CLINICAL TRIAL: PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 主要：描述目前用于妊娠HIV感染妇女临床护理的选定抗逆转录病毒药物在怀孕期间的PK参数，并确定这些抗逆转录病毒药物的标准治疗剂量方案是否在怀孕期间产生足够的药物暴露，与a)来自非怀孕成年人的历史数据；以及b)研究队列中的相同妇女在产后期间。 第二：比较分娩时脐带血和母体血浆中抗逆转录病毒药物的浓度。 通过测定尿液中6b-羟基皮质醇与皮质醇的比值，间接评价细胞色素P450 3A4的诱导作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: PRIMARY: To describe the PK parameters during pregnancy of selected antiretroviral drugs currently used in the clinical care of pregnant HIV-infected women, and to determine if standard therapeutic dosing regimens of these antiretroviral drugs produce adequate drug exposure during pregnancy compared to a) historical data from non-pregnant adults; and b) the same women in the study cohorts during the postpartum period. SECONDARY: To compare antiretroviral drug concentrations in plasma from cord blood with those in maternal plasma at the time of delivery. To indirectly assess the induction of cytochrome P450 3A4 by determining the ratio in urine of 6b-hydroxycortisol to cortisol.